Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in a proenkephalin peptide in cerebrospinal fluid in Huntington's disease and progressive supranuclear

M J Iadarola1, M M Mouradian

  • 1Neurobiology and Anesthesiology Branch, National Institute of Dental Research, Bethesda, MD 20892.

Brain Research
|February 13, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New technologies for studying the complexity of oral diseases.

Oral diseases·2011
Same author

Salivary anti-Ro60 and anti-Ro52 antibody profiles to diagnose Sjogren's Syndrome.

Journal of dental research·2011
Same author

Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action.

Molecular and cellular neurosciences·2009
Same author

Regulation of the expression of proenkephalin mRNA in bovine adrenal chromaffin cells: Role of proto-oncogenes.

Molecular and cellular neurosciences·2009
Same author

Monocyte chemoattractant protein-1 in the choroid plexus: a potential link between vascular pro-inflammatory mediators and the CNS during peripheral tissue inflammation.

Neuroscience·2008
Same author

Imaging of pain: recent developments.

Current opinion in anaesthesiology·2006
Same journal

Targeting neurodevelopmental miR132-3p promotes neuroprotection and axon regeneration after optic nerve injury in mice.

Brain research·2026
Same journal

Variability in acoustic startle response and prepulse inhibition across adulthood in Fragile X messenger ribonucleoprotein 1 knockout mice.

Brain research·2026
Same journal

Transcriptome-guided modeling reveals insulin-related metabolic dysfunction in SCA3 mouse cerebellum.

Brain research·2026
Same journal

Intranasal stromal cell-derived factor-1α mitigates parkinsonian deficits via dual modulation of neuroinflammation and gut microbiota in MPTP-induced models.

Brain research·2026
Same journal

Emotions, the amygdala, and the right hemisphere.

Brain research·2026
Same journal

Electroacupuncture treatment enhances hippocampal growth hormone level and restores mitochondrial function in vascular dementia rats.

Brain research·2026
See all related articles

Cerebrospinal fluid (CSF) levels of Met5-enkephalin-Arg-Gly-Leu were lower in Huntington

Area of Science:

  • Neuroscience
  • Biochemistry

Background:

  • Met5-enkephalin-Arg-Gly-Leu is a peptide derived from the proenkephalin precursor protein.
  • This peptide is typically found in high concentrations within the basal ganglia.
  • Previous research indicates its role in neurological functions.

Purpose of the Study:

  • To investigate the levels of Met5-enkephalin-Arg-Gly-Leu immunoreactivity in cerebrospinal fluid (CSF).
  • To assess the correlation between CSF peptide levels and neurodegenerative diseases like Huntington's disease (HD) and progressive supranuclear palsy (PSP).
  • To determine if CSF peptide levels can serve as a biomarker for basal ganglia neuronal integrity.

Main Methods:

  • Measurement of Met5-enkephalin-Arg-Gly-Leu immunoreactivity in CSF samples from patients.
  • Comparison of CSF peptide levels between patients with HD, PSP, and control groups.

Related Experiment Videos

  • Correlation analysis with known neuropathological findings in HD and PSP.

    • Main Results:

    • Significantly decreased CSF levels of Met5-enkephalin-Arg-Gly-Leu were observed in patients with Huntington's disease.
    • Significantly decreased CSF levels of Met5-enkephalin-Arg-Gly-Leu were observed in patients with progressive supranuclear palsy.
    • The reduction in HD likely reflects neuronal loss in the basal ganglia.
    • The reduction in PSP may indicate functional decline in enkephalinergic activity.

    Conclusions:

    • CSF Met5-enkephalin-Arg-Gly-Leu levels are significantly reduced in Huntington's disease and progressive supranuclear palsy.
    • These findings suggest that CSF Met5-enkephalin-Arg-Gly-Leu originates largely from the basal ganglia.
    • CSF levels of this peptide may serve as a valuable biomarker for assessing the functional and anatomical status of basal ganglia proenkephalin-synthesizing neurons.